Literature DB >> 16819276

The role of the alpha4 integrin-paxillin interaction in regulating leukocyte trafficking.

David M Rose1.   

Abstract

The movement of leukocytes from the blood into peripheral tissues is a central feature of immune surveillance, but also contributes to the pathogenesis of inflammatory and autoimmune diseases. Integrins are a family of adhesion and signaling molecules made up of paired a and beta subunits, and the integrin alpha4beta1 plays a prominent role in the trafficking of mononuclear leukocytes. We have previously described the direct interaction of the signaling adaptor molecule paxillin with the cytoplasmic domain of the alpha4 integrin subunit. This interaction is critical for alpha4beta1 integrin dependent cell adhesion under shear flow conditions as it provides a needed connection to the actin cytoskeleton. Furthermore, the alpha4-paxillin interaction is required for effective alpha4beta1 dependent leukocyte migration and does so through the temporal and spatial regulation of the small GTPase Rac. These findings make the alpha4-paxillin interaction a potentially attractive therapeutic target in controlling leukocyte trafficking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819276     DOI: 10.1038/emm.2006.23

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  11 in total

1.  Distinct changes in adult lymphopoiesis in Rag2-/- mice fully reconstituted by alpha4-deficient adult bone marrow cells.

Authors:  Ena R Banerjee; Yvette E Latchman; Yi Jiang; Greg V Priestley; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2008-05-12       Impact factor: 3.084

2.  Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.

Authors:  Pradeep Sathyanarayana; Madhu P Menon; Olga Bogacheva; Oleg Bogachev; Knut Niss; William S Kapelle; Estelle Houde; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2007-04-02       Impact factor: 22.113

3.  Heparin II domain of fibronectin mediates contractility through an alpha4beta1 co-signaling pathway.

Authors:  Marie K Schwinn; Jose M Gonzalez; B'Ann T Gabelt; Nader Sheibani; Paul L Kaufman; Donna M Peters
Journal:  Exp Cell Res       Date:  2010-03-17       Impact factor: 3.905

4.  IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells.

Authors:  Jing Nie; Benny Chang; Dmitry O Traktuev; Jessica Sun; Keith March; Lawrence Chan; E Helene Sage; Renata Pasqualini; Wadih Arap; Mikhail G Kolonin
Journal:  Stem Cells       Date:  2008-06-26       Impact factor: 6.277

5.  The enabled homolog gene polymorphisms are associated with susceptibility and progression of childhood IgA nephropathy.

Authors:  Won-Ho Hahn; Jin-Soon Suh; Byoung-Soo Cho; Sung-Do Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

6.  ICAM-1/LFA-1 interaction contributes to the induction of endothelial cell-cell separation: implication for enhanced leukocyte diapedesis.

Authors:  Hyun Wee; Hyun-Mee Oh; Jae-Hyeok Jo; Chang-Duk Jun
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

Review 7.  Midkine in inflammation.

Authors:  Ludwig T Weckbach; Takashi Muramatsu; Barbara Walzog
Journal:  ScientificWorldJournal       Date:  2011-12-27

Review 8.  Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy.

Authors:  Margien L Seinen; Geerten P van Nieuw Amerongen; Nanne K H de Boer; Adriaan A van Bodegraven
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

9.  NMR structure of integrin α4 cytosolic tail and its interactions with paxillin.

Authors:  Geok-Lin Chua; Alok Tanala Patra; Suet-Mien Tan; Surajit Bhattacharjya
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  A role for the protein tyrosine phosphatase CD45 in macrophage adhesion through the regulation of paxillin degradation.

Authors:  Joëlle St-Pierre; Hanne L Ostergaard
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.